Carmofur is an antineoplastic agent that has captured attention in the medical community for its potential efficacy in treating various forms of cancer. It’s marketed under different trade names, including Mifurol, and is primarily known for its activity against colorectal cancer.
The development of effective and targeted therapies remains a top priority for both clinicians and pharmaceutical companies. One such therapy, Carmofur, an oral fluoropyrimidine derivative, has proven to be a key agent in the fight against various cancers, particularly colorectal and breast cancer. MedicaPharma, a leading global distributor of GMP-grade Active Pharmaceutical Ingredients (APIs) and raw pharmaceutical materials, is proud to offer Carmofur, a highly effective antineoplastic agent, as part of its comprehensive portfolio. Licensed by the Dutch Ministry of Health, MedicaPharma ensures that all materials meet the highest quality standards, supporting pharmaceutical manufacturers and healthcare providers in delivering life-saving treatments with confidence.
Download GMP-Certified API Product List
MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations. Click here to download our complete API product list.
Get your requested raw materials quotation
Table of Contents
Carmofur is one of the most widely used chemotherapy drugs
Carmofur is a derivative of fluorouracil (5-FU), one of the most widely used chemotherapy drugs in the treatment of various cancers. As an oral formulation, Carmofur offers the advantage of increased convenience and patient compliance compared to intravenous chemotherapies. It is used in the treatment of several cancers, with particular efficacy in the treatment of colorectal cancer, breast cancer, and gastric cancer. In its function as an antineoplastic (anti-cancer) agent, Carmofur works by interfering with the DNA synthesis and cell division of cancer cells, inhibiting tumor growth and spread.
Carmofur is classified as a fluoropyrimidine, similar to fluorouracil, and acts as a potent inhibitor of thymidylate synthase (TS). This enzyme is critical for the synthesis of thymidine, an essential component for DNA replication and repair. By inhibiting thymidylate synthase, Carmofur reduces the availability of thymidine, disrupting DNA synthesis in rapidly dividing cancer cells. This ultimately leads to cell death, particularly in tumor cells that are highly proliferative. Because of this mechanism, Carmofur is most effective in cancers that exhibit rapid cell division, such as colorectal and breast cancers, where uncontrolled cell growth is a hallmark of the disease.
Unlike intravenous 5-FU, which requires administration in a clinical setting, Carmofur is administered orally, offering a more convenient treatment option for patients. This ease of use has contributed to its growing adoption in cancer therapy, as it allows patients to undergo treatment with greater comfort and without the need for frequent hospital visits. Furthermore, the oral formulation has been shown to be equally effective in terms of pharmacokinetics and therapeutic outcomes, allowing clinicians to integrate it into treatment regimens with a similar degree of efficacy to intravenous chemotherapy.
Get your requested raw materials quotation
Carmofur has shown particular promise in treating colorectal cancer
In colorectal cancer, Carmofur has shown particular promise as part of combination chemotherapy regimens. It is often used alongside other agents such as leucovorin and oxaliplatin, contributing to improved treatment outcomes and better survival rates in patients with advanced-stage disease. Carmofur’s ability to enhance the effectiveness of other chemotherapy drugs makes it a valuable addition to multidrug cancer protocols, offering a versatile and effective treatment option for oncologists.
Carmofur is used to treat breast cancer, and gastric cancer
For breast cancer, Carmofur has been studied as part of adjuvant and neoadjuvant chemotherapy regimens. In particular, its use in combination with other agents, such as cyclophosphamide, has demonstrated efficacy in reducing tumor size before surgery and in preventing recurrence following surgical resection. This combination approach helps maximize treatment outcomes, making Carmofur a key component in the arsenal of drugs available to oncologists treating breast cancer.
The clinical application of Carmofur also extends to the treatment of gastric cancer, where it has been integrated into combination therapy regimens that include other chemotherapeutic agents like cisplatin. In these contexts, Carmofur serves as an effective component in reducing tumor burden and improving overall survival, reinforcing its value in global cancer treatment protocols.
Get your requested raw materials quotation
All of MedicaPharma's materials, including Carmofur, are sourced from manufacturers who adhere to the highest Good Manufacturing Practice (GMP) standards.
As pharmaceutical companies and manufacturers look to supply these vital treatments, the importance of sourcing high-quality raw materials cannot be overstated. MedicaPharma specializes in the distribution of GMP-grade raw pharmaceutical materials, ensuring that all Carmofur batches it supplies meet the rigorous standards required for the production of effective, safe, and compliant pharmaceutical products. All of MedicaPharma’s materials, including Carmofur, are sourced from manufacturers who adhere to the highest Good Manufacturing Practice (GMP) standards. This means pharmaceutical companies can be confident that the raw materials they are using are of the highest purity, potency, and consistency, ensuring the integrity of their final products.
The Dutch Ministry of Health’s licensing of MedicaPharma further guarantees that the raw materials provided by the company comply with international regulatory standards. This makes MedicaPharma an ideal partner for pharmaceutical manufacturers seeking to produce Carmofur-based cancer therapies that meet the regulatory requirements for global markets.
In an industry where timely access to high-quality raw materials is crucial, MedicaPharma’s global distribution network ensures that Carmofur is available whenever needed, with fast and reliable delivery options to pharmaceutical manufacturers around the world. MedicaPharma’s commitment to customer service, regulatory compliance, and product excellence makes it the trusted partner for sourcing Carmofur and other critical pharmaceutical materials.
For pharmacists, manufacturers, and healthcare professionals working in oncology, Carmofur is a key material that can make a significant impact in the fight against cancer. Its proven efficacy, broad clinical application, and convenient oral formulation make it an essential component in cancer treatment regimens. By sourcing Carmofur through MedicaPharma, you can ensure that your products meet the highest quality standards and regulatory requirements, ultimately helping to improve patient outcomes and drive the future of cancer care.
Contact MedicaPharma today to learn more about how Carmofur can enhance your oncology offerings and support the ongoing fight against cancer.
Get a Fast and Easy GMP-Certified API Quote
Focus on your compounding pharmacy business and let MedicaPharma take care of your APIs. Obtaining a quote is easy
